SCHEMBL2815669

SCHEMBL2815669

Oc1ccc(-c2cn3c(cnc4ccccc43)n2)c(O)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.44
MAPT P10636 3/20 0.44
ALDH1A1 P00352 3/20 0.44
MEN1 O00255 3/20 0.44
ALOX12 P18054 1/20 0.44
MAPK10 P53779 1/20 0.44
ATM Q13315 1/20 0.44
KDM4E B2RXH2 3/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ADORA2A P29274 2/20 0.40
FGFR1 P11362 2/20 0.40
FYN P06241 1/20 0.39
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ILK Q13418 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2815100 0.87 ALDH1A1 (0.41) KMT2AMAPTALDH1A1MEN1ALOX12
SCHEMBL2816945 0.84 FYN (0.50) RAB9AADORA2AFGFR1FYNHSD17B10
SCHEMBL2818740 0.83 ADORA2A (0.58) KMT2AMAPTALDH1A1MEN1KDM4E
SCHEMBL2814363 0.75 ADORA2A (0.64) ADORA2AADORA1
SCHEMBL2814411 0.74 MAPT (0.40) KMT2AMAPTALDH1A1MEN1ALOX12
SCHEMBL9542204 0.73 BCHE (0.49) KMT2AMAPTALDH1A1MEN1KDM4E
SCHEMBL9539492 0.73 FGFR1 (0.46) KMT2AMAPTALDH1A1ATMKDM4E
SCHEMBL9540820 0.72 ADORA2A (0.58) KMT2AALDH1A1MEN1KDM4ENPC1
SCHEMBL2818999 0.72 TOP2A (0.49) MAPTALDH1A1KDM4ENPC1RAB9A
SCHEMBL9538674 0.71 KDM4E (0.39) KMT2AMAPTALDH1A1MEN1ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS UNIVERSITE DE MONTPELLIER I 2010-09-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS IDH3A, NRAS, KRAS KMT2A 998/4885MAPT 3888/4885ALDH1A1 657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.